NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/06/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization726.25 mln
Float113 mln
Earnings Date08/12/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-4.33
Highly reliable
Relative Strength
89
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
ROE
-54.20
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
Aclaris Therapeutics is a US-based clinical-stage biopharmaceutical company focused on developing new treatments for immune and inflammatory diseases. Founded in 2012 and headquartered in Wayne, Pennsylvania, the company is advancing several drug candidates targeting conditions such as atopic dermatitis, asthma, chronic obstructive pulmonary disease, and other respiratory and autoimmune disorders. Its pipeline spans multiple stages of clinical testing, with therapies designed to work through a range of biological mechanisms that regulate immune cell activity.
